Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Gains from Sales and Divestitures (2016 - 2025)

InspireMD (NSPR) has 10 years of Gains from Sales and Divestitures data on record, last reported at $1.1 million in Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures rose 473.39% year-over-year to $1.1 million; the TTM value through Dec 2024 reached $1.1 million, up 473.39%, while the annual FY2024 figure was $1.1 million, 473.39% up from the prior year.
  • Gains from Sales and Divestitures reached $1.1 million in Q4 2024 per NSPR's latest filing, up from $186510.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.1 million in Q4 2024 and bottomed at $661.0 in Q4 2020.
  • Average Gains from Sales and Divestitures over 5 years is $304043.0, with a median of $186510.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 13120.0% in 2020, then dropped 9.63% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $661.0 in 2020, then surged by 8559.15% to $57237.0 in 2021, then soared by 260.57% to $206379.0 in 2022, then dropped by 9.63% to $186510.0 in 2023, then surged by 473.39% to $1.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.1 million in Q4 2024, $186510.0 in Q4 2023, and $206379.0 in Q4 2022.